CollPlant Issues Letter to Shareholders Rehovot, Israel

CollPlant Issues Letter to Shareholders

Rehovot, Israel, February 15, 2024 - CollPlant Biotechnologies

(Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived

collagen for tissue regeneration and organ manufacturing, is pleased to issue the following letter from its Chief Executive Officer, Yehiel

As we look toward a promising and exciting year ahead, I am proud to

reflect on CollPlant's main achievements throughout 2023. We leveraged our pioneering collagen-based platform and dynamic workforce to

strengthen existing business collaborations, as well as to initiate and advance new opportunities. We continued to develop products with

safety and performance advantages that we believe will lead to further innovation in the fields of regenerative and aesthetic medicine.

We are excited with our progress while remaining extremely focused on advancing our goal to become a global leader in these fields.

During 2023, we made significant progress with our development partner,

AbbVie, to advance our dermal and soft tissue filler toward commercialization. Furthermore, we continue to be engaged in partnering discussions

with several industry leaders seeking to leverage our rhCollagen technology and expertise in 3D bioprinting to develop therapeutics and

medical applications.

Our long-term collaboration with AbbVie to develop a paradigm-shifting

regenerative dermal and soft tissue filler continues to advance. In June of last year, we announced the achievement of an important milestone

under this collaboration which triggered a $10 million payment from AbbVie to CollPlant. Per CollPlant's agreement with AbbVie,

CollPlant has the potential to receive additional milestones and option products payments, as well as receive meaningful royalties on

product sales. AbbVie continues to advance the filler program which is now in clinical studies.

In April of last year, we announced a joint development and commercialization

agreement with Stratasys Ltd. to collaborate on the development of a solution to bio-fabricate human tissues and organs using Stratasys'

P3 technology-based bioprinter and CollPlant's rh-Collagen-based bioinks. The first project focuses on the development of an industrial-scale

solution for CollPlant's regenerative breast implants program. The new bioprinter, based on Stratasys' precise P3 3D printing

technology in combination with CollPlant's flagship bioinks, is designed to enable the production of CollPlant's state of the art

breast implants, which are being developed to regenerate an individual's natural breast tissue without eliciting immune response,

providing a potentially revolutionary alternative for both aesthetic and reconstructive procedures.

Under the agreement, both companies have agreed to cross-promote each

other's bioprinting products. Stratasys' bioprinter will be offered to customers together with CollPlant's bioinks,

and similarly Stratasys' bioprinter will be offered to CollPlant's business partners and customers.

I am proud to share with you a few important highlights from this past

year related to our products pipeline, which targets large commercial opportunities in both, medical aesthetics and personalized medicine

markets. At the cornerstone of our success lies the many advantages of our high-performance non-animal, recombinant human (rh)Collagen.

Regenerative Breast Implants

One of our most exciting products in development is our regenerative

breast implants, addressing the $2.6 billion global breast implant market. Additionally, breast reconstruction and augmentation procedures

represent the second most common plastic surgery procedure performed worldwide today. The most common breast augmentation or reconstruction

procedures today are based on synthetic silicone breast implantations, an artificial substitution for natural regenerated tissue with

risks of complications.

Currently, there are no commercial products that allow regeneration

of soft tissues such as the breast. In the U.S. alone, hundreds of thousands of people per year experience adverse events that range from

autoimmune symptoms to the very serious breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). CollPlant's breast implants

that are comprised of the Company's proprietary plant-derived rhCollagen and other biomaterials, are expected to regenerate breast tissue

without eliciting immune response, and thus may provide a revolutionary alternative for aesthetic and reconstructive procedures, including

postmastectomy for cancer patients.

In January of last year, we announced the successful completion of

a large animal study for our recombinant human collagen (rhCollagen)-based 3D bioprinted regenerative breast implants. The preclinical

study demonstrated progressive stages of tissue regeneration after three months, as highlighted by the formation of maturing connective

tissue and neovascular networks within the implants, with no adverse events reported. This study was followed by additional large animal

studies that were intended to further optimize the implant design and composition. New tissue formation and neovascularization with no

adverse tissue reactions were demonstrated confirming previous results.

Supported by these promising results, in December 2023, we initiated

a large-animal study to evaluate commercial-size,3D-bioprinted, regenerative breast implants. This study will be used to obtain data that

will be used to support subsequent human studies and future product commercialization.

The achievements we demonstrated to date take us another step forward

in the development of a revolutionary alternative to silicone implants for aesthetic and reconstructive procedures.

Gut-on-a-Chip Tissue Model

CollPlant decided in 2022 to expand into the promising field of personalized

medicine. Our lead program in this space is our gut-on-a-chip program that is addressing the need to provide therapeutic choices for inflammatory

bowel diseases. Our specific focus is on ulcerative colitis, or UC.

We are developing a bioprinted human intestine model that can be used

in drug discovery and personalized treatment of UC. The 3D bioprinted model is designed to emulate the human intestine tissue in order

to allow medical professionals to identify drug targets and personalized therapeutic responses that can lead to improved patient outcomes.

We remain extremely excited about the prospects for this program and

plan to provide an update with the next steps for this program as we enter the next phase of development.

Intellectual Property

In November of last year, we announced that the U.S. Patent and Trademark

Office has granted a patent that covers CollPlant's photocurable dermal filler product candidate, being developed for the aesthetics market.

The U.S. Patent (No. 11,801,329) is directed, among other things, to

a method of filling tissue space under the epidermis by introducing a polymerizable filler solution into the tissue space and applying

external light to induce in-situ polymerization. This newly issued patent is related to CollPlant's photocuring technology and serves

as the basis of our photocurable dermal filler product pipeline currently under development. The polymerizable solution injected into

the tissue space is comprised of a chemically modified recombinant human collagen (rhCollagen) and other constituents such as hyaluronic

This patent represents an integral part of the Company's strategy to

expand the uses for its novel, rhCollagen technology into new, high-value markets. The U.S. is one of CollPlant's strategic target markets,

and we see the strengthening of our intellectual property in this territory as a significant achievement.

In addition to its superior skin lifting capacity, the photocurable

filler is designed to enable tissue regeneration and tissue contouring ability. This issued patent expiring in 2039 provides coverage

for a regenerative photocurable dermal filler with contouring capabilities and we believe this will strengthen our position in the market

for many years to come.

Corporate Responsibility

Our rhCollagen production process utilizes plant-based genetic engineering

technology. This approach eliminates the need for traditional animal-derived collagen sources, reducing the environmental strain associated

with traditional methods and promoting more ethical and sustainable practices.

In the second quarter of 2023, CollPlant hired a dedicated expert to

lead our Environment, Social and Governance (ESG) effort. Our goal was to identify CollPlant's strengths in the areas of ESG that

are already in line with our mission and communicate these practices to business partners and the public.

In line with this initiative,

in September last year, CollPlant announced that it joined the United Nations Global Compact, the world's largest initiative for sustainable

and responsible corporate governance. As a new participant of this voluntary leadership platform, CollPlant strengthens its commitment

to operate sustainably as it is also producing sustainable alternatives to the regenerative and aesthetics medicine products and technologies

that currently exist.

Consistent with our mission of helping people live longer, healthier

lives through regenerative medicine, we are committed to supporting a more sustainable ecosystem that benefits all stakeholders, including

patients, our employees, and our shareholders.

Tissue and organ shortage is a major medical challenge arising from

a combination of donor scarcity and patient rejection. As technologies evolve with 3D bioprinting technology, we believe this will enable

CollPlant to address the challenge by utilizing our rhCollagen to help to create an unlimited supply of tissues and organs.

Additionally, as we develop tissue models that can mimic a variety

of human disease conditions, this will be a driver for our strategic expansion into personalized medicine.

In 2024, we plan to further advance and expand our diverse portfolio

of innovative products and value-creating partnerships, alongside our commitment to support a more sustainable and equitable world.